{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:58:49Z","timestamp":1787896729671,"version":"build-2784847793"},"reference-count":27,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beca-SEPAR 2019"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The diversity of patients with malignant pleural effusion (MPE) due to non-small cell lung cancer (NSCLC) as well as the variability in mutations makes it essential to improve molecular characterization. Objective: Describe clinical, pathological, and molecular characteristics MPE in a Caucasian population. Materials and\u00a0Methods: Retrospective study of patients with NSCLC diagnosis who had undergone a molecular study from 1 January 2018\u201331 December 2022. Univariate analysis was performed to compare patient characteristics between the group with and without MPE and molecular biomarkers. Results: A total of 400 patients were included; 53% presented any biomarker and 29% had MPE.PDL1, which was the most frequent. EGFR mutation was associated with women (OR:3.873) and lack of smoking (OR:5.105), but not with MPE. Patients with pleural effusion were older and had lower ECOG. There was no significant difference in the presence of any biomarker. We also did not find an association between the presence of specific mutations and MPE (22.4% vs. 18%, p = 0.2), or PDL1 expression (31.9% vs. 35.9%, p = 0.3). Being younger constituted a protective factor for the presence of MPE (OR:0.962; 95% CI 0.939\u20130.985, p = 0.002), as well as ECOG \u2264 1 (OR:0.539; 95% CI 0.322\u20130.902, p = 0.01). Conclusions: This is the first study that describes the clinical, pathological, and molecular characteristics of MPE patients due to NSCLC in a Caucasian population. Although overall we did not find significant differences in the molecular profile between patients with MPE and without effusion, EGFR mutation was associated with a tendency towards pleural progression.<\/jats:p>","DOI":"10.3390\/medicina60111804","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:57:34Z","timestamp":1730692654000},"page":"1804","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and Molecular Features of Malignant Pleural Effusion in Non-Small Cell Lung Cancer (NSCLC) of a Caucasian Population"],"prefix":"10.3390","volume":"60","author":[{"given":"Irene","family":"Lojo-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Botana-Rial","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), CIBERES-ISCIII, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Gonz\u00e1lez-Montaos","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Leiro-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), CIBERES-ISCIII, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pi\u00f1eiro","sequence":"additional","affiliation":[{"name":"Pathology Department, Alvaro Cunqueiro Hospital, Spain PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-7810","authenticated-orcid":false,"given":"Cristina","family":"Ramos-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fern\u00e1ndez-Villar","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Alvaro Cunqueiro Hospital, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), CIBERES-ISCIII, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1753466618785098","DOI":"10.1177\/1753466618785098","article-title":"Contemporary best practice in the management of malignant pleural effusion","volume":"12","author":"Koegelenberg","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ccm.2021.08.004","article-title":"Malignant Pleural Effusions","volume":"42","author":"Kapp","year":"2021","journal-title":"Clin. Chest Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Addala, D.N., Kanellakis, N.I., Bedawi, E.O., Dong, T., and Rahman, N.M. (2022). Malignant pleural effusion: Updates in diagnosis, management and current challenges. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1053574"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","article-title":"Lung cancer: Epidemiology, etiology, and prevention","volume":"32","author":"Tanoue","year":"2011","journal-title":"Clin. Chest Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Boshoff. Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic Therapy for Locally Advanced and metastatic Non\u2013Small Cell Lung Cancer. A Review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/cncr.34757","article-title":"Targeted therapy for lung cancer: Beyond EGFR and ALK","volume":"129","year":"2023","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/ajco.12658","article-title":"Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment","volume":"13","author":"Wang","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1570163813666160524142846","article-title":"Can EGFR-tyrosine kinase inhibitors (TKI) alone without talc pleurodesis prevent recurrence of malignant pleural effusion (MPE) in lung adenocarcinoma","volume":"13","author":"Verma","year":"2016","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/crj.13005","article-title":"Novel insights into the systemic treatment of lung cancer malignant pleural effusion","volume":"13","author":"Tissot","year":"2019","journal-title":"Clin. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"150","article-title":"Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes","volume":"23","author":"Haiyue","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/0300060514539273","article-title":"Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation","volume":"42","author":"Zou","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2019.05.018","article-title":"Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung","volume":"135","author":"Wang","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cllc.2011.02.006","article-title":"EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases","volume":"12","author":"Han","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Grigoriadou, G.I., Esagian, S.M., Ryu, H.S., and Nikas, I.P. (2020). Molecular profiling of malignant pleural effusions with next generation sequencing (NGS): Evidence that supports Its role in cancer management. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040206"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rmr.2011.03.005","article-title":"A simple view on lung cancer biology: The EGFR pathway","volume":"28","author":"Ruppert","year":"2011","journal-title":"Rev. Mal. Respir."},{"key":"ref_20","first-page":"1021","article-title":"Pleural involvement in lung cancer","volume":"7","author":"Agalioti","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_21","first-page":"142","article-title":"Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens","volume":"20","author":"Xu","year":"2015","journal-title":"J. BUON"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cyt.12322","article-title":"Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer","volume":"27","author":"Zhong","year":"2016","journal-title":"Cytopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/gcc.22647","article-title":"Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion","volume":"57","author":"Wu","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/1759-7714.13004","article-title":"Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer","volume":"10","author":"Shibaki","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000477148","article-title":"Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis","volume":"61","author":"Shabihkhani","year":"2017","journal-title":"Acta Cytol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.arbres.2022.09.017","article-title":"Diagnosis and treatment of pleural effusion. Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery. Update 2022","volume":"59","author":"Porcel","year":"2023","journal-title":"Arch. Bronconeumol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1800349","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur. Respir. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1804\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:38Z","timestamp":1760113658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["medicina60111804"],"URL":"https:\/\/doi.org\/10.3390\/medicina60111804","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]}}}